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ABSTRACT  
Objective: To develop and validate UV spectrometric method for quantitative determination of ulipristal acetate. 
Methods: The solvent selected was methanol and detection was carried out at 302 nm.  
Results: Linearity of the proposed method was found to be between 5–20 μg/ml. LOD and LOQ were found to be 0.0062 μg/ml and 0.0187 μg/ml, 
respectively. The % recovery of the proposed method was found to be 98.83 %-100.32 %. The method was found to be precise as the values of % 
RSD obtained for both intraday and interday, precision studies were found to be<2.0 %. The method was robust and can be useful for routine 
analysis of formulations containing ulipristal acetate. 
Conclusion: The developed method was found to be simple, sensitive, linear, accurate, precise and robust. The developed and validated method can 
be used for quantitative determination of ulipristal acetate in bulk drugs and dosage form. 
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INTRODUCTION  
Ulipristal acetate (UPA), chemically 19-norprogesterone [17 alpha-
acetoxy-11-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-
3,20-dione](fig. 1), is a progesterone receptor modulator with 
contraceptive potential. It is white amorphous powder, sparingly 
soluble in water and freely soluble in methanol, acetonitrile and 
chloroform. UPA prevents progesterone from binding to the 
receptor, leading to blockage of gene transcription inhibiting 
synthesis of proteins necessary to begin and maintain pregnancy [1]. 
It also acts by inhibiting the ovulation. The drug has also shown 
potential in the treatment of uterine fibroids [2, 3]. Ulipristal acetate 
is available in tablet dosage form (ella One 30 mg) [4, 5]. 
 
 
Fig. 1: Structure of ulipristal acetate 
 
As per literature review, no UV spectrometric method is reported for 
quantitative estimation of ulipristal acetate. Hence, the aim of the 
present study was to develop and validate a fast, simple, selective, 
sensitive and inexpensive UV spectrometric method for the 
quantitative estimation of ulipristal acetate in tablet dosage form. 
A double beam Agilent cary 60 UV-visible spectrophotometer and 
single beam Thermo Electron Corporation Helious α UV-visible 
spectrophotometer were used. Standard of ulipristal acetate was 
obtained as gift sample from authentic source. Methanol AR used as 
solvent was procured from Rankem (RFCL), Gujarat, India. 
Standard stock solution containing ulipristal acetate was prepared 
by dissolving 10 mg of drug in 50 ml of methanol, it was then 
sonicated for 10 minutes and the final volume of the solution was 
made up to 100 ml with methanol to get stock solution containing 
100 μg/ml of ulipristal acetate. For test solution, twenty tablets of 
ulipristal acetate (each tablet containing 30 mg of ulipristal acetate) 
were weighed; average weight was calculated and triturated. 
Accurately weighed tablet powder containing 25 mg of ulipristal 
acetate was transferred to a 250 ml of volumetric flask. About 50 ml 
of methanol was added to the flask and sonicated for 15 min. The 
volume of the solution was made up to the mark to get solution 
containing 100μg/ml of ulipristal acetate. The resulting solution was 
then filtered through a Whatman filter paper followed by syringe 
filter (Sartorius stedim biotech, Minisart).  
Methanol was selected as solvent as the drug was found to be freely 
soluble in it. All the measurements were carried out at 302 nm 
which corresponds to absorbance maxima of the drug (fig. 2 & 3). 
 
 
Fig. 2: UV spectrum of standard solution (10 µg/ml) 
 
The developed method was validated as per ICH guidelines for 
various parameters such as specificity, linearity and range, LOD & 
LOQ, accuracy, precision and robustness [6]. 
The specificity of an analytical method is its ability to assess 
unequivocally the analyte in the presence of other components. 
Specificity was evaluated by comparison of spectra of 10 μg/ml of 
standard and test solutions containing UPA. The method was found 
to be specific as no interference was observed from the components 
present in the tablets. 
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The linearity of proposed method was evaluated by analyzing 
different concentration of the standard solutions of UPA in the range 
of 5–20 μg/ml. Absorbance of each solution was measured in 
triplicate at 302 nm using methanol as blank. A plot of average 
absorbance vs concentration was plotted and regression coefficient 
(R2
 
Fig. 3: UVspectrum of test solution (10 µg/ml) 
) was found to be 0.9991(fig. 4, table 1). 
 
 
Detection limit and quantitation limit represents sensitivity of the 
method. The LOD and LOQ of UPA were determined using standard 
deviation method. Calibration curve was prepared in the detection 
and quantitation range (1–6 μg/ml) and LOD and LOQ were 
determined using formula 3.3 σ/S and 10 σ/S, respectively, where S 
is the slope of the calibration curve and σ is the standard deviation 
of y–intercepts of calibration line. The LOD and LOQ of the proposed 
method were found to be 0.0062 µg/ml and 0.0187 µg/ml, 
respectively (table 1). 
 
 
Fig. 4: Calibration curve of ulipristal acetate 
Table 1: Results of quantitative determination of ulipristal acetate 
S. No. Parameters Results* 
1 Absorbance maximum (nm)  302 
2 Linearity and Range (µg/ml) 5–20  
3 Slope  0.1301 
4 Intercept  0.1360 
5 Correlation coefficient  0.9991 
6 LOD (µg/ml) 0.0062 
7 LOQ(µg/ml) 0.0187 
*n = 3 (triplicate measurements) 
 
To ascertain the accuracy of the proposed method, recovery studies 
were carried at three different concentration levels. Known amount 
of standard UPA solution (5μg/ml, 10 μg/ml, 15μg/ml) was added to 
pre analyzed test sample (2 μg/ml) and absorbance was recorded in 
triplicates.  
Percent recovery for UPA at each level was calculated using formula: 
(Measured value/True value) x 100. Recovery at each level for the 
proposed method was found between 98.83 %-100.32 % with % 
RSD not more than 2.0 % (table 2) indicating the accuracy of the 
method. 
 
Table 2: Results of accuracy studies of proposed method 
Level Amount added % Recovery*±S. D. % RSD* 
 Standard (µg/ml) Test(µg/ml)   
50 % 5 2 100.32±0.12 0.1218 
100 % 10 2 98.83±0.06 0.0687 
150 % 15 2 99.12±0.03 0.0374 
*n = 3 (triplicate measurements) 
 
The precision of the method was demonstrated by intraday and 
interday precision studies. In intraday precision studies, test 
samples were prepared at three concentration levels(5 μg/ml, 10 
μg/ml, 15μg/ml) and absorbance were measured at different time 
intervals. While interday precision studies were carried out by 
analyzing sample solutions at three concentration levels for three 
different days. % RSD was determined for each concentration level. 
The values of % RSD obtained at each level of intraday and interday 
precision studies were less than 2 (table 3). Hence, the method was 
found to be precise. 
  
Table 3: Results of precision studies of proposed method 
Conc (µg/ml) Intraday precision (% RSD) Interday precision (% RSD)* * 
 Day 1 Day 1 Day 1 Day 2 Day 3 
5 0.0000 0.0254 0.0756 0.0952 0.0266 
10 0.0222 0.0129 0.0128 0.0129 0.0225 
15 0.0538 0.0389 0.0306 0.0752 0.0085 
*n = 3 (triplicate measurements) 
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The robustness of the proposed method was evaluated by varying 
method parameters such as different analysts (analyst 1, analyst 2), 
wavelengths (301 nm, 303 nm) and instruments (Agilent cary 60 UV-
visible spectrophotometer, Thermo Electron Corporation Helious α 
UV-visible spectrophotometer). The robustness was assessed by 
analyzing standard solutions of 10 μg/ml (n = 6) and the sample 
solution of 2 μg/ml (n = 2) of UPA and % RSD was calculated. The low 
values of % RSD obtained after small deliberate changes of conditions 
used for the method indicate that the method was robust (table 4). 
The in-house tablets containing 30 mg of UPA was prepared and 
analyzed. The content of UPA in tablets was found to be 102.20±0.00 
table 5. 
 
Table 4: Results of robustness studies of proposed method 
Parameters Absorbance±S. D. % RSD* Content of UPA (mg)±S. D.* (mg) * 
Analyst 
 
Analyst 1 0.5621±0.00 0.0145 29.66±0.00 
Analyst 2 0.5596±0.00 0.0246 29.66±0.00 
Wavelength 
 
301 nm 0.5602±0.00 0.0281 30.00±0.00 
303 nm 0.5701±0.00 0.0143 29.33±0.00 
Instruments 
 
Agilent cary 60 0.5622±0.00 0.0331 29.66±0.17 
Thermo Electron Corporation 0.5611±0.00 0.0776 29.66±0.00 
*n = 6 (six measurements) 
 
Table 5: Analysis of in-house tablets 
Conc (µg/ml) Absorbance Label claim (mg) Amount obtained*±S. D. % Assay*±S. D. 
10 0.5456 30 30.66±0.00 102.20±0.00 
0.5450 
0.5451 
*n = 3 (triplicate measurements) 
 
The proposed UV method is simple, sensitive, accurate, precise and 
robust. The proposed method is inexpensive and do not require any 
sophisticated apparatus in contrast to chromatographic methods. 
The method can be successfully used for routine quality control 
analysis of the formulation containing UPA. 
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